Recommended

Find out more on ‘AI & Informatics: Drug discovery and development’ in our exclusive report
Download your complimentary copy of our latest digital journal
Free membership: sign up today to access all of our exclusive content
Hear from industry leaders in our upcoming webinars – reserve your place today!
article

Antibodies In-Depth Focus 2020

Posted: 24 March 2020 | | No comments yet

This In-Depth Focus includes articles on antibodies as a treatment for COVID-19, the importance of understanding every aspect of an ADC and the potential of antibodies as a targeted cancer therapeutic.

Antibodies In-Depth Focus

    To read this in-depth focus in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


    *


    *


    *


    *


    *


    *


    *


    *

    This content is provided to you for free thanks to the kind support of our sponsors: MilliporeSigma, Berkeley Lights, ForteBio

    Included in this in-depth focus:

    • The race to find a coronavirus treatment: are antibodies the answer?
      At the beginning of March, US President Donald Trump pressed the pharmaceutical industry to “accelerate the development” of vaccines and therapies to contain the outbreak of the coronavirus pandemic. This article explores what is currently known about COVID-19 and potential treatments that are in the pipeline.
    • Not everyone loves surprises: know your ADC’s critical quality attributes
      The importance of product characterisation throughout the entire drug development process cannot be understated. Success, money and lives depend on it. This article delves into why you need to understand every aspect of an ADC in order to prevent unwelcome surprises down the line.
    • Antibodies allow for a targeted approach to cancer therapy
      Cancer can be an immovable beast, tenacious in its numerous mechanisms to thrive and grow. However, the healthcare industry has an ever-expanding arsenal of therapies designed to thwart it, with variable levels of success. Nikki Withers speaks to Dr Jill O’Donnell-Tormey, CEO and Director of Scientific Affairs at the Cancer Research Institute (CRI), who explains why antibodies have the edge over other targeted drugs.